Mon Sep 16 15:18:00 UTC 2024: ## Shareholder Lawsuit Filed Against Allarity Therapeutics Over Misleading Statements
**Atlanta, Georgia** – A class action lawsuit has been filed against Allarity Therapeutics, Inc. (NASDAQ: ALLR), alleging that the company made misleading statements about its drug development and regulatory prospects. The suit, filed on September 16, 2024, claims that Allarity overstated the chances of its Dovitinib drug gaining regulatory approval, and failed to disclose potential legal and regulatory risks associated with the drug’s development.
The lawsuit also accuses Allarity and three of its former officers of engaging in improper conduct related to the drug’s applications for approval. The plaintiffs allege that these actions have put the company at risk of facing regulatory scrutiny and potential enforcement action, which could result in significant financial and reputational damage.
The lawsuit covers investors who bought shares of Allarity between May 17, 2022 and July 19, 2024, and experienced losses on their investments. The lead plaintiff deadline for the case is November 12, 2024.
Holzer & Holzer, LLC, the law firm representing the plaintiffs, encourages affected investors to contact them to discuss their legal options. The firm specializes in shareholder litigation and has a history of recovering millions of dollars for investors harmed by corporate misconduct.
First Piper 